John DeLuca, PhD: Ozanimod Resulted in Improved Cognitive Processing Speed in Relapsing MS
March 30th 2019The Senior Vice President for Research and Training at Kessler Foundation discussed the results of the SUNBEAM trial, which indicated that ozanimod resulted in sustained improvement in cognitive processing speed, supporting its efficacy in relapsing MS.
Mark Freedman, MD: Early Intervention With Interferon Beta-1b for Patients Presenting With CIS
March 28th 2019The director of the multiple sclerosis research unit at Ottawa Hospital spoke about the results of BENEFIT 15 that support early intervention of interferon beta-1b treatment at or shortly after CIS.
David Leppert, MD: Building a Foundation for Neurofilament Light
March 22nd 2019The therapeutic head of neuroinflammation and pain at Novartis spoke about his desire to work to a point where physicians can use NfL to monitor disease activity, make therapeutic decisions, and give perspective to patients.
Antje Bischof, MD: Accelerated Cord Atrophy Precedes Conversion to SPMS in RRMS
March 19th 2019The Postdoctoral Scholar at the University of California San Francisco spoke about a longitudinal study that evaluated the utility of spinal cord atrophy measured from brain scans as a surrogate marker for impending conversion to secondary progressive MS.
Dina Katabi, PhD: Biosensors for Measuring Disease Activity in MS and Other Neurological Disorders
March 13th 2019The Andrew & Erna Viterbi Professor of Electrical Engineering and Computer Science at MIT spoke about a new way of continuous monitoring for patients with MS and neurodegenerative disorders, discovering changes in quality of life and new biomarkers.
Fred Lublin, MD: Current Challenges in MS
March 11th 2019The director of the Corinne Goldsmith Dickinson Center for MS at Mount Sinai School of Medicine spoke about the major issues in MS right now: being able to individually prognosticate, moving toward developing better therapies for a progressive disease, and repairing the damage to the nervous system.